FLT3 and acute myeloid leukemia: Although no survival benefit of the second-generation FLT3-inhibitor gilteritinib + AZA combination has been shown in the NCT02752035 trial, improved efficacy was reported in NCT03625505 with gilteritinib + VEN in the case of R/R AML [60, 61].